The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.42% | -3.43% | 8.73% | 10.84% | 2.15% | -0.34% | 15.12% | 15.62% | N/A | N/A | 11.13% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.42% | -3.43% | 8.73% | 10.84% | 2.15% | -0.69% | 52.64% | 78.8% | N/A | N/A | 68.56% |
| Rank within category | 10/19 | 10/18 | 14/18 | 12/18 | 15/17 | 14/14 | 11/12 | 10/10 | N/A | N/A | N/A |
| Sector Funds | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -8.68% | 31.61% | 41.25% | -9.96% | 7.41% |
| Q1 returns | N/A | -7.3% | -4.62% | 9.63% | -10.24% | -6.15% |
| Q2 returns | N/A | -9.48% | 14.79% | 4.52% | 4.99% | 17.75% |
| Q3 returns | N/A | 8.78% | 8.11% | 19.84% | -3.86% | 1.85% |
| Q4 returns | N/A | 0.04% | 11.2% | 2.86% | -0.62% | -4.57% |
0.50% on or before 3M, NIL after 3M
| Alpha | -0.190634 |
| Beta | 0.9937 |
| Sharpe Ratio | 0.218357 |
| Sortino Ratio | 0.446212 |
| R-Squared | 0.8815 |
| Tracking Error | 1.4667 |
| Downside Risk | 19.5056 |
| Std. Deviation (Annualised) | 14.9066 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth Current | -7.42% | -3.43% | 8.73% | 10.84% | 2.15% | 15.12% | N/A | N/A | 11.13% | 266.05 | 2.62 | 0.22 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.96% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.51% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.45% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 4.49% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.19% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.02% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.01% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.78% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.14% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.09% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.07% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 2.85% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.77% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.14% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.94% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.87% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.61% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 1.59% |
| Poly Medicure Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 1.48% |
| Healthcare Global Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.47% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.27% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.25% |
| Shaily Engineering Plastics Ltd. | Consumer Durables | Domestic Equities | 1.22% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.13% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.03% |
| Supriya Lifescience Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.00% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 1.00% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.96% |
| Linde India Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.92% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.81% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.73% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 0.71% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.71% | |
| Caplin Point Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.68% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.57% |
| Total | 100.00% | ||
Mr. Nilay Dalal joined ITI Asset Management Limited in April 2023 and has over 12 years of work experience in financial markets.
He is an investment management professional with over 20 years of experience in portfolio management, equity research, and investment advisory services. Prior to Joinig ITI AMC, he served as Director - Investment & Portfolio Manager at Julius Baer Wealth Advisory, where he managed Alternative Investment Fund portfolios and advised clients on investment strategies across asset classes. Prior to this, he held senior roles at Centrum Wealth and Nippon Life India Asset Management, managing equity advisory portfolios, PMS mandates, and institutional investment portfolios. He began his career in equity research and credit analysis, covering sectors such as telecom, media, FMCG, and automobiles.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
